In the PACIFIC trial, durvalumab provided significant OS benefit to patients with unresectable, stage 3 NSCLC. Although many patients received additional treatment with immunotherapy after discontinuation, this did not affect OS outcomes.
Historically, the standard of care for patients with unresectable, stage 3 NSCLC has been platinum-based chemoradiation. However, outcomes have been poor with approximately 15-30% of patients being alive after 5 years . Before the approval of ICIs changed the treatment paradigm, several studies investigated systemic therapy with curative intent after disease control with chemoradiation. However, none demonstrated improved survival .
In the world-wide phase 3 PACIFIC trial, patients with stage 3 NSCLC without progression after chemoradiation and with good performance status, received either durvalumab or placebo. Recent analyses showed that both primary endpoints were met, with significant improvements of PFS ...
Please login to read the full text of the article.